Pairnomix Announces Attendance At 2017 Fall Conferences

PLYMOUTH, Minn., Oct. 5, 2017 /PRNewswire/ -- Pairnomix, LLC, a personalized genetic evaluations company, today announced that it will have a presence at six upcoming medical and scientific conferences. The company will be presenting data from recent case studies that focus on epileptic encephalopathies. The conferences Pairnomix will attend include:

• The Child Neurology Society (CNS) 2017 Annual Meeting, October 4-7, 2017 in Kansas City, MO
• Exhibit Booth #522
• Poster Presentation; October 5, 12:30 pm – 2:00 pm and 4:30 pm - 6:00 pm CT; October 6, 7:00 am – 8:15 am CT
                                                                             
• Individualizing Medicine 2017 Conference, October 9-10, 2017 in Rochester, MN
• Poster Presentation; October 9, 5:00 pm – 7:30 pm CT
                                                                             
• American Society of Human Genetics (ASHG) 2017 Annual Meeting, October 17-22, 2017 in Orlando, FL
• Exhibit Booth #829
• Poster Presentation; October 19, 3:00 pm – 4:00 pm ET
                                                                             
• KCNQ2 Cure Summit, October 22-24, 2017 in Boston, MA
• Pairnomix CEO, Matthew Fox to deliver a talk on October 24, 9:00 am – 9:30 am ET. The KCNQ2 Cure Summit is designed to unite all groups committed to improving the lives of those with KCNQ2 epilepsy.
                                                                             
• Society for Neuroscience (SfN) Annual Meeting, November 11-15, 2017 in Washington, DC
• Poster Presentation; November 12, 8:00 am – 12:00 pm ET
                                                                             
• American Epilepsy Society (AES) Annual Meeting, December 1-5, 2017 in Washington, DC
• Exhibit Booth #228
• Poster Presentation; Poster Session 3; December 4, 12:00 pm – 2:00 pm ET

About Pairnomix 
Pairnomix™, a personalized genetic evaluations company, is committed to helping people living with rare diseases understand the genetic cause of their condition and explore potential treatment options that are available today. Pairnomix's initial focus is on advancing personalized research for people living with epilepsy and other disorders of the Central Nervous System. To learn more, please visit www.pairnomix.com.

SOURCE Pairnomix, LLC

Related Links

http://www.pairnomix.com